Quantcast

Latest treatment of multiple sclerosis Stories

2009-04-15 08:46:00

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...

2009-04-14 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. This was the fourth of several regularly...

2009-04-13 07:53:50

Patients with multiple sclerosis (MS) may soon have more treatment options for their disease. A new report in Chemical & Engineering News says years of scientific research on MS means 11 potential new drugs are now in the final stages of clinical trials and may soon be on pharmacy shelves. Those drugs could double the number of medications available to treat MS over the next several years. Many of the new drugs are pills rather than injections. This makes it easier for patients to take...

2009-03-17 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008. "Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President...

2009-03-16 15:30:00

BELGRADE, March 16 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in...

2009-03-02 16:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009. On March 18, 2008, BioMS Medical's Board of Directors passed a...

2009-02-05 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York. WHEN: Monday February 9th at 2:45pm (Eastern Time) WHERE: Waldorf-Astoria, New York City About BIO CEO & Investor Conference...

2009-02-04 07:00:00

Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States,...

2008-12-11 16:30:00

Toronto Stock Exchange Symbol: MS EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company was the recipient of the "Licensing Deal of the Year Award" at the 4th Annual Scrip Awards held in London, U.K. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide rights to dirucotide, for the treatment of...

2008-11-06 03:00:20

Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided. The presentation will include the Phase III projects laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, which is licensed...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related